skip to Main Content

All Press Releases

Pila Pharma AB is granted Orphan Drug Designation status in the USA

Malmö 15 July 2022 Download the press release as PDF here Pila Pharma AB (publ) announces that the US Food and Drug Administration, FDA, has granted Orphan Drug Designation (ODD) of the development candidate XEN-D0501 for treatment of erythromelalgia, a rare disease that causes episodes of burning pain and redness due to neurogenic inflammation. Pila Pharma's candidate molecule XEN-D0501 is…

Read more

VD Dorte X. Gram ökar sitt innehav i Pila Pharma AB

Malmö, 1 juli, 2022 Läs pressmeddelandet som PDF här Pila Pharma AB (publ) meddelar att VD Dorte X. Gram under torsdagen den 30 juni köpt 12 700 aktier i bolaget.  Aktierna köptes till en snittkurs om 3,93 SEK. Affären har skett genom bolaget Gram Equity Invest som hon äger tillsammans med sin son Gustav Hanghøj Gram. Dorte X. Gram är…

Read more

CEO Dorte X. Gram increases holding in Pila Pharma AB

Malmö, July 1, 2022 Download the press release as PDF here Pila Pharma AB (publ) announces that CEO Dorte X. Gram on Thursday, June 30, bought 12,700 shares in the company. The shares were purchased at an average price of SEK 3.93. The transaction took place through the company Gram Equity Invest, which she owns together with her son Gustav…

Read more

Contact us

FÅ PRESSMEDDELANDEN
GET PRESS RELEASES

Back To Top
Search